IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION

CourtDistrict Court, S.D. New York
DecidedMarch 7, 2022
Docket1:19-cv-01578
StatusUnknown

This text of IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION (IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION, (S.D.N.Y. 2022).

Opinion

UNITED STATES DISTRICT COURT DOC #: DATE FILED: 3/7/20 22 SOUTHERN DISTRICT OF NEW YORK -------------------------------------------------------------- X : 19-CV-1578 (VEC) IN RE: NAVIDEA BIOPHARMACEUTICALS : LITIGATION : OPINION AND ORDER : -------------------------------------------------------------- X VALERIE CAPRONI, United States District Judge: This Court is called upon, once again, to decide whether and to what extend Plaintiff Navidea Biopharmaceuticals, Inc. (“Navidea”) should be required to advance legal fees incurred by Defendant Michael Goldberg (“Goldberg”) in defending this action. Now before the Court is Navidea’s August 6, 2021, motion for reconsideration of the Court’s August 24, 2020 Opinion and Order, which held, inter alia, that Navidea was legally obligated to advance to Goldberg the fees he reasonably incurred in defending against Navidea’s remaining claims in this case. See Mot. for Recons., Dkt. 218; Op. & Order, Dkt. 134 (“Aug. 24, 2020 Order”). On August 9, 2021, the Undersigned referred Navidea’s motion for reconsideration to Magistrate Judge Freeman for a Report and Recommendation (“R&R”). See Am. Order, Dkt. 221. On October 14, 2021, Magistrate Judge Freeman issued an R&R recommending that the Court deny Navidea’s motion because: (1) it is untimely; and (2) lacks merit. See R&R, Dkt. 231 at 12–17. On October 28, and October 29, 2021, respectively, Goldberg and Navidea submitted objections to the R&R. See Dkts. 236, 239.1 For the following reason, the Court ADOPTS the R&R in part.

1 Goldberg filed two identical objections at docket entries 236 and 237; all references here will be to docket entry 236. BACKGROUND The Court assumes familiarity with the Court’s prior opinions issued over the course of this more-than-three-year litigation and will summarize only the most pertinent facts. Navidea sued Goldberg for breach of contract, breach of the covenant of good faith and fair dealing, breach of fiduciary duty, and for a declaratory judgment establishing the contractual rights and

obligations of the parties. See Am. Compl., Dkt. 15. Goldberg asserted counterclaims against Navidea and third-party claims against Macrophage Therapeutics, Inc. (“Macrophage”), a subsidiary of Navidea. See Answer, Dkt. 31. Goldberg moved to dismiss Plaintiff’s breach of fiduciary duty claim and sought attorneys’ fees in connection with litigating that claim. See Mot. to Dismiss, Dkt. 32. On December 26, 2019, the Undersigned granted Goldberg’s motion to dismiss the breach of fiduciary duty claim and determined that he was entitled to attorneys’ fees with respect to his defense of that claim. See Op. & Order, Dkt. 61. The Court directed the parties to meet and confer regarding an appropriate amount of attorneys’ fees; on February 20, 2020, Goldberg informed the Court that the parties were unable to reach an agreement on an

amount. See Goldberg Ltr., Dkt. 78. Goldberg also filed a separate motion for advancement of: (1) attorneys’ fees incurred in litigating Navidea’s remaining claims; and (2) fees incurred in litigating claims brought by Macrophage against him in an entirely separate proceeding in Delaware Chancery Court. See Mot. for Attorneys’ Fees, Dkt. 64. On February 20, 2020, the Undersigned referred those motions to Magistrate Judge Freeman for a report and recommendation. See Order, Dkt. 80. On July 9, 2020, Magistrate Judge Freeman issued an R&R (“July R&R”) that recommended, inter alia, that: (1) the Court find that Goldberg was entitled to indemnification for attorneys’ fees reasonably incurred in defending the breach of fiduciary duty claim; and (2) the Court find that Goldberg was entitled to advancement of attorneys’ fees reasonably incurred to that date in litigating Navidea’s remaining claims. See R&R, Dkt. 119. On August 24, 2020, the Court adopted the July R&R in full. See Aug. 24, 2020 Order. The Court held that Goldberg was entitled to indemnification for attorneys’ fees reasonably incurred in litigating the breach of fiduciary duty claim and is entitled to advancement of

attorneys’ fees reasonably incurred in litigating Navidea’s remaining claims, provided he tenders the necessary undertaking to repay the advancement if it is ultimately determined that he is not entitled to indemnification under Navidea’s bylaws. Id. at 5–9.2 On June 23, 2021, after a trial in the separate proceeding between Goldberg and Macrophage, the Delaware Chancery Court rejected Macrophage’s claim for conversion but determined that its breach-of-fiduciary-duty claim had merit. See Decl. of Barry Kazan, Dkt. 220 at Ex. 1 at 35–47, 57–61 (Op. & Order, Macrophage Therapeutics, Inc. v. Goldberg, C.A. No. 2019-0137 (Del. Ch. June 23, 2021) [“Delaware Decision”]). The Delaware court found that Goldberg “took matters into his own hands,” “to effectuate what he believed he was owed under

the [] Agreement.” Id. at 2. The court held that Goldberg was not legally entitled to do so because he stood on both sides of the challenged transactions, making him a “conflicted fiduciary”, and requiring him to prove that the transactions were the product of fair dealing and resulted in a fair price. See id. at 37–38. Goldberg failed to do so at trial; accordingly, the Delaware court concluded that he violated his duty of loyalty to Macrophage’s stockholders. See id. at 46.3

2 The Court declined to exercise ancillary jurisdiction over Goldberg’s application for advancement of the attorneys’ fees he incurred in litigating Macrophage’s claims in the Delaware action, noting, inter alia, that “[n]ot only is Navidea not a party to the Delaware Action, but the two cases present different types of claims stemming from different conduct.” Aug. 24, 2020 Order at 4.

3 For this breach, however, the court awarded Macrophage nominal damages of $1.00, as it found that Macrophage had not demonstrated any actual loss. See Delaware Decision at 47–53. The court also declined to On August 6, 2021, Navidea moved for reconsideration of this Court’s August 24, 2020 Order, arguing that the Delaware Decision constitutes new evidence or changed circumstances that warrant reconsideration. See Navidea Mem. of Law, Dkt. 219 at 1.4 Navidea argues that, because the Delaware court found that Goldberg had breached his duty of loyalty to Macrophage’s stockholders, it not only adjudicated Goldberg liable to Macrophage but also to

Navidea, Macrophage’s majority stockholder. See id. at 11–12. In light of that decision, Navidea argues, Goldberg has no right under Navidea’s Bylaws to indemnification.5 Absent a right to indemnification, Navidea argues, Goldberg also has no right to advancement of his fees or costs in connection with any of Navidea’s remaining claims. See id. at 12–13. Accordingly, Navidea argues, Goldberg should be required to repay the $1,237.50 that Navidea advanced to him pursuant to the August 24 Order. See id. at 12–13; see also Op. & Order, Dkt. 207 at 13– 14.6 Goldberg, in response, argues that Navidea’s motion is based on the false premise “that a determination by a separate court in a separate action that Dr. Goldberg was liable to a different

party on a single claim entirely different in kind from the ones at issue here” means that

award Macrophage its attorneys’ fees, finding that Goldberg’s conduct was not sufficiently egregious to justify such an award. See id. at 54–57.

4 Navidea is not challenging the Court’s ruling that Goldberg was entitled to indemnification for the fees and costs he incurred in litigating the breach-of-fiduciary-duty claim that was dismissed. See Aug. 24, 2020 Order at 5 (“Navidea does not object to the Court making this finding.”) (citing Navidea Obj., Dkt. 122 at 8 n.2); see also generally Navidea Mem. of Law. Navidea is only challenging the Court’s ruling that it must advance Goldberg’s attorneys’ fees reasonably incurred in litigating Navidea’s remaining claims. See Navidea Mem.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Stevens v. Miller
676 F.3d 62 (Second Circuit, 2012)
Bruce C. Shrader v. Csx Transportation, Inc.
70 F.3d 255 (Second Circuit, 1995)
United States v. Male Juvenile (95-Cr-1074)
121 F.3d 34 (Second Circuit, 1997)
Shomo v. City of New York
579 F.3d 176 (Second Circuit, 2009)
Ortiz v. Barkley
558 F. Supp. 2d 444 (S.D. New York, 2008)
Wilds v. United Parcel Service, Inc.
262 F. Supp. 2d 163 (S.D. New York, 2003)
Bjs v. State Educ. department/university of Ny
699 F. Supp. 2d 586 (W.D. New York, 2010)
In Re Health Management Systems, Inc. Securities Litigation
113 F. Supp. 2d 613 (S.D. New York, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-navidea-biopharmaceuticals-litigation-nysd-2022.